nodes	percent_of_prediction	percent_of_DWPC	metapath
Fosaprepitant—TACR1—Peptide GPCRs—CCR9—Crohn's disease	0.0263	0.0634	CbGpPWpGaD
Fosaprepitant—TACR1—SIDS Susceptibility Pathways—CREM—Crohn's disease	0.0191	0.0461	CbGpPWpGaD
Fosaprepitant—TACR1—Peptide ligand-binding receptors—ACKR2—Crohn's disease	0.0188	0.0454	CbGpPWpGaD
Fosaprepitant—TACR1—G alpha (q) signalling events—MLN—Crohn's disease	0.0181	0.0436	CbGpPWpGaD
Fosaprepitant—TACR1—Peptide ligand-binding receptors—MLN—Crohn's disease	0.0178	0.043	CbGpPWpGaD
Fosaprepitant—TACR1—Peptide GPCRs—CCR6—Crohn's disease	0.0174	0.042	CbGpPWpGaD
Fosaprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—MLN—Crohn's disease	0.0161	0.039	CbGpPWpGaD
Fosaprepitant—Prurigo—Mesalazine—Crohn's disease	0.0154	0.0262	CcSEcCtD
Fosaprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—ACKR2—Crohn's disease	0.0126	0.0305	CbGpPWpGaD
Fosaprepitant—Candida infection—Mercaptopurine—Crohn's disease	0.0125	0.0213	CcSEcCtD
Fosaprepitant—TACR1—Peptide ligand-binding receptors—CCR9—Crohn's disease	0.0124	0.0298	CbGpPWpGaD
Fosaprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—MLN—Crohn's disease	0.012	0.0289	CbGpPWpGaD
Fosaprepitant—TACR1—G alpha (q) signalling events—GPR65—Crohn's disease	0.0116	0.0281	CbGpPWpGaD
Fosaprepitant—Upset stomach—Mesalazine—Crohn's disease	0.0108	0.0185	CcSEcCtD
Fosaprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—GPR65—Crohn's disease	0.0104	0.0251	CbGpPWpGaD
Fosaprepitant—Blood potassium decreased—Prednisone—Crohn's disease	0.00988	0.0169	CcSEcCtD
Fosaprepitant—TACR1—GPCR ligand binding—ACKR2—Crohn's disease	0.0096	0.0232	CbGpPWpGaD
Fosaprepitant—Neoplasm malignant—Azathioprine—Crohn's disease	0.00912	0.0156	CcSEcCtD
Fosaprepitant—TACR1—GPCR ligand binding—MLN—Crohn's disease	0.0091	0.022	CbGpPWpGaD
Fosaprepitant—Cognitive disorder—Prednisone—Crohn's disease	0.00868	0.0148	CcSEcCtD
Fosaprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—CCR9—Crohn's disease	0.00829	0.02	CbGpPWpGaD
Fosaprepitant—TACR1—Peptide ligand-binding receptors—CCR6—Crohn's disease	0.00818	0.0198	CbGpPWpGaD
Fosaprepitant—Oropharyngeal pain—Mesalazine—Crohn's disease	0.0078	0.0133	CcSEcCtD
Fosaprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—GPR65—Crohn's disease	0.0077	0.0186	CbGpPWpGaD
Fosaprepitant—Blood bilirubin increased—Mesalazine—Crohn's disease	0.0075	0.0128	CcSEcCtD
Fosaprepitant—Stomatitis—Mercaptopurine—Crohn's disease	0.00713	0.0122	CcSEcCtD
Fosaprepitant—Eructation—Mesalazine—Crohn's disease	0.00697	0.0119	CcSEcCtD
Fosaprepitant—Candida infection—Mesalazine—Crohn's disease	0.00678	0.0116	CcSEcCtD
Fosaprepitant—TACR1—GPCR ligand binding—CCR9—Crohn's disease	0.00631	0.0152	CbGpPWpGaD
Fosaprepitant—Febrile neutropenia—Prednisone—Crohn's disease	0.00624	0.0107	CcSEcCtD
Fosaprepitant—TACR1—G alpha (q) signalling events—RASGRP1—Crohn's disease	0.00601	0.0145	CbGpPWpGaD
Fosaprepitant—Immune system disorder—Mercaptopurine—Crohn's disease	0.00593	0.0101	CcSEcCtD
Fosaprepitant—Blood alkaline phosphatase increased—Mesalazine—Crohn's disease	0.00592	0.0101	CcSEcCtD
Fosaprepitant—TACR1—GPCR ligand binding—GPR65—Crohn's disease	0.00587	0.0142	CbGpPWpGaD
Fosaprepitant—Disorientation—Mesalazine—Crohn's disease	0.00576	0.00983	CcSEcCtD
Fosaprepitant—Malnutrition—Mercaptopurine—Crohn's disease	0.00572	0.00976	CcSEcCtD
Fosaprepitant—TACR1—Spinal Cord Injury—TLR4—Crohn's disease	0.00569	0.0137	CbGpPWpGaD
Fosaprepitant—TACR1—SIDS Susceptibility Pathways—IL10—Crohn's disease	0.00565	0.0136	CbGpPWpGaD
Fosaprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—CCR6—Crohn's disease	0.00549	0.0133	CbGpPWpGaD
Fosaprepitant—TACR1—Spinal Cord Injury—ICAM1—Crohn's disease	0.00546	0.0132	CbGpPWpGaD
Fosaprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—RASGRP1—Crohn's disease	0.00538	0.013	CbGpPWpGaD
Fosaprepitant—Anaemia—Mercaptopurine—Crohn's disease	0.00528	0.00902	CcSEcCtD
Fosaprepitant—Lethargy—Mesalazine—Crohn's disease	0.00526	0.00897	CcSEcCtD
Fosaprepitant—Osteoarthritis—Mesalazine—Crohn's disease	0.00515	0.00879	CcSEcCtD
Fosaprepitant—TACR1—GPCR downstream signaling—MLN—Crohn's disease	0.00514	0.0124	CbGpPWpGaD
Fosaprepitant—Toxic epidermal necrolysis—Azathioprine—Crohn's disease	0.00509	0.00869	CcSEcCtD
Fosaprepitant—TACR1—Signaling by GPCR—ACKR2—Crohn's disease	0.00493	0.0119	CbGpPWpGaD
Fosaprepitant—Unspecified disorder of skin and subcutaneous tissue—Mercaptopurine—Crohn's disease	0.00483	0.00825	CcSEcCtD
Fosaprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—PTGER4—Crohn's disease	0.00483	0.0117	CbGpPWpGaD
Fosaprepitant—Abdominal pain upper—Mesalazine—Crohn's disease	0.0047	0.00803	CcSEcCtD
Fosaprepitant—Abdominal discomfort—Azathioprine—Crohn's disease	0.00469	0.008	CcSEcCtD
Fosaprepitant—TACR1—Signaling by GPCR—MLN—Crohn's disease	0.00467	0.0113	CbGpPWpGaD
Fosaprepitant—Oedema—Mercaptopurine—Crohn's disease	0.00467	0.00796	CcSEcCtD
Fosaprepitant—Aspartate aminotransferase increased—Mesalazine—Crohn's disease	0.00464	0.00792	CcSEcCtD
Fosaprepitant—Glycosuria—Prednisone—Crohn's disease	0.00463	0.00791	CcSEcCtD
Fosaprepitant—Alanine aminotransferase increased—Mesalazine—Crohn's disease	0.00454	0.00775	CcSEcCtD
Fosaprepitant—Skin disorder—Mercaptopurine—Crohn's disease	0.00453	0.00773	CcSEcCtD
Fosaprepitant—Abdominal distension—Mesalazine—Crohn's disease	0.00448	0.00765	CcSEcCtD
Fosaprepitant—Infestation NOS—Azathioprine—Crohn's disease	0.00436	0.00744	CcSEcCtD
Fosaprepitant—Infestation—Azathioprine—Crohn's disease	0.00436	0.00744	CcSEcCtD
Fosaprepitant—Stevens-Johnson syndrome—Azathioprine—Crohn's disease	0.00432	0.00737	CcSEcCtD
Fosaprepitant—Abdominal discomfort—Mesalazine—Crohn's disease	0.00427	0.00729	CcSEcCtD
Fosaprepitant—TACR1—GPCR ligand binding—CCR6—Crohn's disease	0.00418	0.0101	CbGpPWpGaD
Fosaprepitant—Dysuria—Mesalazine—Crohn's disease	0.00416	0.00711	CcSEcCtD
Fosaprepitant—TACR1—Spinal Cord Injury—IFNG—Crohn's disease	0.00415	0.01	CbGpPWpGaD
Fosaprepitant—Pollakiuria—Mesalazine—Crohn's disease	0.00411	0.00702	CcSEcCtD
Fosaprepitant—Photosensitivity reaction—Mesalazine—Crohn's disease	0.00406	0.00694	CcSEcCtD
Fosaprepitant—Decreased appetite—Mercaptopurine—Crohn's disease	0.00406	0.00692	CcSEcCtD
Fosaprepitant—Weight decreased—Mesalazine—Crohn's disease	0.00403	0.00688	CcSEcCtD
Fosaprepitant—Gastrointestinal disorder—Mercaptopurine—Crohn's disease	0.00403	0.00687	CcSEcCtD
Fosaprepitant—TACR1—Spinal Cord Injury—PTGS2—Crohn's disease	0.00398	0.00961	CbGpPWpGaD
Fosaprepitant—Infestation—Mesalazine—Crohn's disease	0.00397	0.00678	CcSEcCtD
Fosaprepitant—Infestation NOS—Mesalazine—Crohn's disease	0.00397	0.00678	CcSEcCtD
Fosaprepitant—Stevens-Johnson syndrome—Mesalazine—Crohn's disease	0.00394	0.00672	CcSEcCtD
Fosaprepitant—Stomatitis—Mesalazine—Crohn's disease	0.00387	0.0066	CcSEcCtD
Fosaprepitant—TACR1—Spinal Cord Injury—CXCL8—Crohn's disease	0.00386	0.00932	CbGpPWpGaD
Fosaprepitant—Conjunctivitis—Mesalazine—Crohn's disease	0.00386	0.00659	CcSEcCtD
Fosaprepitant—Urinary tract infection—Mesalazine—Crohn's disease	0.00386	0.00659	CcSEcCtD
Fosaprepitant—Haematuria—Mesalazine—Crohn's disease	0.00379	0.00646	CcSEcCtD
Fosaprepitant—Hiccups—Prednisone—Crohn's disease	0.00375	0.00641	CcSEcCtD
Fosaprepitant—TACR1—Spinal Cord Injury—IL1B—Crohn's disease	0.0037	0.00894	CbGpPWpGaD
Fosaprepitant—Erythema multiforme—Azathioprine—Crohn's disease	0.0037	0.00631	CcSEcCtD
Fosaprepitant—Body temperature increased—Mercaptopurine—Crohn's disease	0.00369	0.00629	CcSEcCtD
Fosaprepitant—TACR1—GPCR ligand binding—PTGER4—Crohn's disease	0.00368	0.00889	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—CCR9—Crohn's disease	0.00357	0.00861	CbGpPWpGaD
Fosaprepitant—Immune system disorder—Azathioprine—Crohn's disease	0.00353	0.00603	CcSEcCtD
Fosaprepitant—Mediastinal disorder—Azathioprine—Crohn's disease	0.00353	0.00602	CcSEcCtD
Fosaprepitant—Urinary tract disorder—Mesalazine—Crohn's disease	0.00352	0.00601	CcSEcCtD
Fosaprepitant—Connective tissue disorder—Mesalazine—Crohn's disease	0.0035	0.00598	CcSEcCtD
Fosaprepitant—Urethral disorder—Mesalazine—Crohn's disease	0.00349	0.00596	CcSEcCtD
Fosaprepitant—Hypersensitivity—Mercaptopurine—Crohn's disease	0.00344	0.00587	CcSEcCtD
Fosaprepitant—Erythema multiforme—Mesalazine—Crohn's disease	0.00337	0.00575	CcSEcCtD
Fosaprepitant—Eye disorder—Mesalazine—Crohn's disease	0.00333	0.00568	CcSEcCtD
Fosaprepitant—Tinnitus—Mesalazine—Crohn's disease	0.00332	0.00567	CcSEcCtD
Fosaprepitant—TACR1—GPCR downstream signaling—GPR65—Crohn's disease	0.00332	0.00801	CbGpPWpGaD
Fosaprepitant—Cardiac disorder—Mesalazine—Crohn's disease	0.00331	0.00565	CcSEcCtD
Fosaprepitant—TACR1—Signaling by GPCR—CCR9—Crohn's disease	0.00324	0.00782	CbGpPWpGaD
Fosaprepitant—Angiopathy—Mesalazine—Crohn's disease	0.00323	0.00552	CcSEcCtD
Fosaprepitant—Euphoric mood—Prednisone—Crohn's disease	0.00323	0.00551	CcSEcCtD
Fosaprepitant—Immune system disorder—Mesalazine—Crohn's disease	0.00322	0.00549	CcSEcCtD
Fosaprepitant—Mediastinal disorder—Mesalazine—Crohn's disease	0.00321	0.00548	CcSEcCtD
Fosaprepitant—Diarrhoea—Mercaptopurine—Crohn's disease	0.00319	0.00545	CcSEcCtD
Fosaprepitant—Ill-defined disorder—Azathioprine—Crohn's disease	0.00316	0.00539	CcSEcCtD
Fosaprepitant—Thrombophlebitis—Prednisone—Crohn's disease	0.00315	0.00537	CcSEcCtD
Fosaprepitant—Anaemia—Azathioprine—Crohn's disease	0.00315	0.00537	CcSEcCtD
Fosaprepitant—Mental disorder—Mesalazine—Crohn's disease	0.00312	0.00533	CcSEcCtD
Fosaprepitant—Erythema—Mesalazine—Crohn's disease	0.0031	0.0053	CcSEcCtD
Fosaprepitant—TACR1—SIDS Susceptibility Pathways—CXCL8—Crohn's disease	0.00309	0.00746	CbGpPWpGaD
Fosaprepitant—Malaise—Azathioprine—Crohn's disease	0.00307	0.00524	CcSEcCtD
Fosaprepitant—Flatulence—Mesalazine—Crohn's disease	0.00306	0.00522	CcSEcCtD
Fosaprepitant—Dysgeusia—Mesalazine—Crohn's disease	0.00304	0.00519	CcSEcCtD
Fosaprepitant—TACR1—Signaling by GPCR—GPR65—Crohn's disease	0.00301	0.00727	CbGpPWpGaD
Fosaprepitant—Muscle spasms—Mesalazine—Crohn's disease	0.00298	0.00509	CcSEcCtD
Fosaprepitant—Vomiting—Mercaptopurine—Crohn's disease	0.00297	0.00506	CcSEcCtD
Fosaprepitant—TACR1—SIDS Susceptibility Pathways—IL1B—Crohn's disease	0.00296	0.00715	CbGpPWpGaD
Fosaprepitant—Rash—Mercaptopurine—Crohn's disease	0.00294	0.00502	CcSEcCtD
Fosaprepitant—Dermatitis—Mercaptopurine—Crohn's disease	0.00294	0.00502	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—ACKR2—Crohn's disease	0.00291	0.00703	CbGpPWpGaD
Fosaprepitant—Unspecified disorder of skin and subcutaneous tissue—Azathioprine—Crohn's disease	0.00288	0.00492	CcSEcCtD
Fosaprepitant—Ill-defined disorder—Mesalazine—Crohn's disease	0.00288	0.00491	CcSEcCtD
Fosaprepitant—Anaemia—Mesalazine—Crohn's disease	0.00287	0.00489	CcSEcCtD
Fosaprepitant—Discomfort—Azathioprine—Crohn's disease	0.00286	0.00489	CcSEcCtD
Fosaprepitant—Angioedema—Mesalazine—Crohn's disease	0.00283	0.00484	CcSEcCtD
Fosaprepitant—Malaise—Mesalazine—Crohn's disease	0.0028	0.00478	CcSEcCtD
Fosaprepitant—Syncope—Mesalazine—Crohn's disease	0.00278	0.00475	CcSEcCtD
Fosaprepitant—Lethargy—Prednisone—Crohn's disease	0.00278	0.00475	CcSEcCtD
Fosaprepitant—Nausea—Mercaptopurine—Crohn's disease	0.00277	0.00473	CcSEcCtD
Fosaprepitant—Infection—Azathioprine—Crohn's disease	0.00276	0.00471	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—MLN—Crohn's disease	0.00276	0.00666	CbGpPWpGaD
Fosaprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—Crohn's disease	0.00274	0.00662	CbGpPWpGaD
Fosaprepitant—Palpitations—Mesalazine—Crohn's disease	0.00274	0.00468	CcSEcCtD
Fosaprepitant—Loss of consciousness—Mesalazine—Crohn's disease	0.00273	0.00465	CcSEcCtD
Fosaprepitant—Osteoarthritis—Prednisone—Crohn's disease	0.00273	0.00465	CcSEcCtD
Fosaprepitant—Cough—Mesalazine—Crohn's disease	0.00271	0.00462	CcSEcCtD
Fosaprepitant—Skin disorder—Azathioprine—Crohn's disease	0.0027	0.00461	CcSEcCtD
Fosaprepitant—TACR1—Spinal Cord Injury—TNF—Crohn's disease	0.00269	0.00649	CbGpPWpGaD
Fosaprepitant—Hypertension—Mesalazine—Crohn's disease	0.00268	0.00457	CcSEcCtD
Fosaprepitant—Chest pain—Mesalazine—Crohn's disease	0.00264	0.00451	CcSEcCtD
Fosaprepitant—TACR1—Peptide ligand-binding receptors—CXCL8—Crohn's disease	0.00264	0.00637	CbGpPWpGaD
Fosaprepitant—Anxiety—Mesalazine—Crohn's disease	0.00263	0.00449	CcSEcCtD
Fosaprepitant—Unspecified disorder of skin and subcutaneous tissue—Mesalazine—Crohn's disease	0.00262	0.00448	CcSEcCtD
Fosaprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—JAK2—Crohn's disease	0.00262	0.00632	CbGpPWpGaD
Fosaprepitant—Discomfort—Mesalazine—Crohn's disease	0.00261	0.00445	CcSEcCtD
Fosaprepitant—Hypotension—Azathioprine—Crohn's disease	0.0026	0.00443	CcSEcCtD
Fosaprepitant—Dry mouth—Mesalazine—Crohn's disease	0.00258	0.00441	CcSEcCtD
Fosaprepitant—Oedema—Mesalazine—Crohn's disease	0.00253	0.00432	CcSEcCtD
Fosaprepitant—Anaphylactic shock—Mesalazine—Crohn's disease	0.00253	0.00432	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—TAGAP—Crohn's disease	0.00252	0.0061	CbGpPWpGaD
Fosaprepitant—Infection—Mesalazine—Crohn's disease	0.00252	0.00429	CcSEcCtD
Fosaprepitant—Shock—Mesalazine—Crohn's disease	0.00249	0.00425	CcSEcCtD
Fosaprepitant—Nervous system disorder—Mesalazine—Crohn's disease	0.00248	0.00424	CcSEcCtD
Fosaprepitant—Hypokalaemia—Prednisone—Crohn's disease	0.00248	0.00423	CcSEcCtD
Fosaprepitant—Skin disorder—Mesalazine—Crohn's disease	0.00246	0.0042	CcSEcCtD
Fosaprepitant—Hyperhidrosis—Mesalazine—Crohn's disease	0.00245	0.00418	CcSEcCtD
Fosaprepitant—Muscular weakness—Prednisone—Crohn's disease	0.0024	0.0041	CcSEcCtD
Fosaprepitant—Alanine aminotransferase increased—Prednisone—Crohn's disease	0.0024	0.0041	CcSEcCtD
Fosaprepitant—Gastrointestinal disorder—Azathioprine—Crohn's disease	0.0024	0.0041	CcSEcCtD
Fosaprepitant—Abdominal distension—Prednisone—Crohn's disease	0.00237	0.00405	CcSEcCtD
Fosaprepitant—Hypotension—Mesalazine—Crohn's disease	0.00237	0.00404	CcSEcCtD
Fosaprepitant—TACR1—GPCR downstream signaling—CCR6—Crohn's disease	0.00236	0.0057	CbGpPWpGaD
Fosaprepitant—Feeling abnormal—Azathioprine—Crohn's disease	0.00229	0.00391	CcSEcCtD
Fosaprepitant—Insomnia—Mesalazine—Crohn's disease	0.00229	0.00391	CcSEcCtD
Fosaprepitant—Gastrointestinal pain—Azathioprine—Crohn's disease	0.00227	0.00388	CcSEcCtD
Fosaprepitant—Dyspnoea—Mesalazine—Crohn's disease	0.00226	0.00385	CcSEcCtD
Fosaprepitant—Somnolence—Mesalazine—Crohn's disease	0.00225	0.00384	CcSEcCtD
Fosaprepitant—Dyspepsia—Mesalazine—Crohn's disease	0.00223	0.0038	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—RSPO3—Crohn's disease	0.00221	0.00533	CbGpPWpGaD
Fosaprepitant—Decreased appetite—Mesalazine—Crohn's disease	0.0022	0.00376	CcSEcCtD
Fosaprepitant—Body temperature increased—Azathioprine—Crohn's disease	0.0022	0.00375	CcSEcCtD
Fosaprepitant—Abdominal pain—Azathioprine—Crohn's disease	0.0022	0.00375	CcSEcCtD
Fosaprepitant—Gastrointestinal disorder—Mesalazine—Crohn's disease	0.00219	0.00373	CcSEcCtD
Fosaprepitant—Fatigue—Mesalazine—Crohn's disease	0.00218	0.00373	CcSEcCtD
Fosaprepitant—TACR1—Spinal Cord Injury—IL6—Crohn's disease	0.00217	0.00524	CbGpPWpGaD
Fosaprepitant—Pain—Mesalazine—Crohn's disease	0.00217	0.0037	CcSEcCtD
Fosaprepitant—Constipation—Mesalazine—Crohn's disease	0.00217	0.0037	CcSEcCtD
Fosaprepitant—TACR1—SIDS Susceptibility Pathways—TNF—Crohn's disease	0.00215	0.00519	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—CCR6—Crohn's disease	0.00215	0.00518	CbGpPWpGaD
Fosaprepitant—Weight decreased—Prednisone—Crohn's disease	0.00213	0.00364	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—SEL1L—Crohn's disease	0.00209	0.00505	CbGpPWpGaD
Fosaprepitant—Feeling abnormal—Mesalazine—Crohn's disease	0.00209	0.00356	CcSEcCtD
Fosaprepitant—TACR1—GPCR downstream signaling—PTGER4—Crohn's disease	0.00208	0.00502	CbGpPWpGaD
Fosaprepitant—Gastrointestinal pain—Mesalazine—Crohn's disease	0.00207	0.00353	CcSEcCtD
Fosaprepitant—Hypersensitivity—Azathioprine—Crohn's disease	0.00205	0.0035	CcSEcCtD
Fosaprepitant—Urticaria—Mesalazine—Crohn's disease	0.00201	0.00343	CcSEcCtD
Fosaprepitant—Abdominal pain—Mesalazine—Crohn's disease	0.002	0.00342	CcSEcCtD
Fosaprepitant—Body temperature increased—Mesalazine—Crohn's disease	0.002	0.00342	CcSEcCtD
Fosaprepitant—Bradycardia—Prednisone—Crohn's disease	0.00192	0.00328	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—CCR9—Crohn's disease	0.00191	0.00462	CbGpPWpGaD
Fosaprepitant—Diarrhoea—Azathioprine—Crohn's disease	0.0019	0.00325	CcSEcCtD
Fosaprepitant—TACR1—Signaling by GPCR—PTGER4—Crohn's disease	0.00189	0.00456	CbGpPWpGaD
Fosaprepitant—Hypersensitivity—Mesalazine—Crohn's disease	0.00187	0.00318	CcSEcCtD
Fosaprepitant—Connective tissue disorder—Prednisone—Crohn's disease	0.00185	0.00316	CcSEcCtD
Fosaprepitant—Dizziness—Azathioprine—Crohn's disease	0.00184	0.00314	CcSEcCtD
Fosaprepitant—Asthenia—Mesalazine—Crohn's disease	0.00182	0.0031	CcSEcCtD
Fosaprepitant—Pruritus—Mesalazine—Crohn's disease	0.00179	0.00306	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—GPR65—Crohn's disease	0.00178	0.00429	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—IL3—Crohn's disease	0.00177	0.00428	CbGpPWpGaD
Fosaprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—CXCL8—Crohn's disease	0.00177	0.00427	CbGpPWpGaD
Fosaprepitant—Vomiting—Azathioprine—Crohn's disease	0.00177	0.00302	CcSEcCtD
Fosaprepitant—Eye disorder—Prednisone—Crohn's disease	0.00176	0.00301	CcSEcCtD
Fosaprepitant—Rash—Azathioprine—Crohn's disease	0.00175	0.00299	CcSEcCtD
Fosaprepitant—Dermatitis—Azathioprine—Crohn's disease	0.00175	0.00299	CcSEcCtD
Fosaprepitant—Flushing—Prednisone—Crohn's disease	0.00175	0.00299	CcSEcCtD
Fosaprepitant—Headache—Azathioprine—Crohn's disease	0.00174	0.00297	CcSEcCtD
Fosaprepitant—TACR1—SIDS Susceptibility Pathways—IL6—Crohn's disease	0.00173	0.00419	CbGpPWpGaD
Fosaprepitant—Diarrhoea—Mesalazine—Crohn's disease	0.00173	0.00296	CcSEcCtD
Fosaprepitant—TACR1—GPCR downstream signaling—RASGRP1—Crohn's disease	0.00171	0.00414	CbGpPWpGaD
Fosaprepitant—Angiopathy—Prednisone—Crohn's disease	0.00171	0.00292	CcSEcCtD
Fosaprepitant—Immune system disorder—Prednisone—Crohn's disease	0.0017	0.00291	CcSEcCtD
Fosaprepitant—Dizziness—Mesalazine—Crohn's disease	0.00167	0.00286	CcSEcCtD
Fosaprepitant—Mental disorder—Prednisone—Crohn's disease	0.00165	0.00282	CcSEcCtD
Fosaprepitant—Nausea—Azathioprine—Crohn's disease	0.00165	0.00282	CcSEcCtD
Fosaprepitant—Erythema—Prednisone—Crohn's disease	0.00164	0.0028	CcSEcCtD
Fosaprepitant—Malnutrition—Prednisone—Crohn's disease	0.00164	0.0028	CcSEcCtD
Fosaprepitant—Vomiting—Mesalazine—Crohn's disease	0.00161	0.00275	CcSEcCtD
Fosaprepitant—TACR1—Signaling by GPCR—IL3—Crohn's disease	0.00161	0.00388	CbGpPWpGaD
Fosaprepitant—Rash—Mesalazine—Crohn's disease	0.0016	0.00272	CcSEcCtD
Fosaprepitant—Dermatitis—Mesalazine—Crohn's disease	0.00159	0.00272	CcSEcCtD
Fosaprepitant—Headache—Mesalazine—Crohn's disease	0.00159	0.00271	CcSEcCtD
Fosaprepitant—TACR1—Signaling by GPCR—RASGRP1—Crohn's disease	0.00156	0.00376	CbGpPWpGaD
Fosaprepitant—Ill-defined disorder—Prednisone—Crohn's disease	0.00152	0.0026	CcSEcCtD
Fosaprepitant—Anaemia—Prednisone—Crohn's disease	0.00152	0.00259	CcSEcCtD
Fosaprepitant—Nausea—Mesalazine—Crohn's disease	0.0015	0.00257	CcSEcCtD
Fosaprepitant—Angioedema—Prednisone—Crohn's disease	0.0015	0.00256	CcSEcCtD
Fosaprepitant—Malaise—Prednisone—Crohn's disease	0.00148	0.00253	CcSEcCtD
Fosaprepitant—Syncope—Prednisone—Crohn's disease	0.00147	0.00251	CcSEcCtD
Fosaprepitant—Loss of consciousness—Prednisone—Crohn's disease	0.00144	0.00246	CcSEcCtD
Fosaprepitant—Hypertension—Prednisone—Crohn's disease	0.00142	0.00242	CcSEcCtD
Fosaprepitant—Anxiety—Prednisone—Crohn's disease	0.00139	0.00238	CcSEcCtD
Fosaprepitant—Unspecified disorder of skin and subcutaneous tissue—Prednisone—Crohn's disease	0.00139	0.00237	CcSEcCtD
Fosaprepitant—Discomfort—Prednisone—Crohn's disease	0.00138	0.00236	CcSEcCtD
Fosaprepitant—TACR1—GPCR ligand binding—CXCL8—Crohn's disease	0.00135	0.00325	CbGpPWpGaD
Fosaprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—Crohn's disease	0.00134	0.00324	CbGpPWpGaD
Fosaprepitant—Oedema—Prednisone—Crohn's disease	0.00134	0.00229	CcSEcCtD
Fosaprepitant—Anaphylactic shock—Prednisone—Crohn's disease	0.00134	0.00229	CcSEcCtD
Fosaprepitant—Infection—Prednisone—Crohn's disease	0.00133	0.00227	CcSEcCtD
Fosaprepitant—Shock—Prednisone—Crohn's disease	0.00132	0.00225	CcSEcCtD
Fosaprepitant—Nervous system disorder—Prednisone—Crohn's disease	0.00131	0.00224	CcSEcCtD
Fosaprepitant—Skin disorder—Prednisone—Crohn's disease	0.0013	0.00222	CcSEcCtD
Fosaprepitant—Hyperhidrosis—Prednisone—Crohn's disease	0.0013	0.00221	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—CCR6—Crohn's disease	0.00127	0.00306	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—IL2RA—Crohn's disease	0.00124	0.003	CbGpPWpGaD
Fosaprepitant—Insomnia—Prednisone—Crohn's disease	0.00121	0.00207	CcSEcCtD
Fosaprepitant—Dyspepsia—Prednisone—Crohn's disease	0.00118	0.00201	CcSEcCtD
Fosaprepitant—Decreased appetite—Prednisone—Crohn's disease	0.00116	0.00199	CcSEcCtD
Fosaprepitant—Fatigue—Prednisone—Crohn's disease	0.00115	0.00197	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—RBX1—Crohn's disease	0.00115	0.00277	CbGpPWpGaD
Fosaprepitant—Constipation—Prednisone—Crohn's disease	0.00115	0.00196	CcSEcCtD
Fosaprepitant—TACR1—Signaling by GPCR—IL2RA—Crohn's disease	0.00113	0.00272	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—PTGER4—Crohn's disease	0.00112	0.00269	CbGpPWpGaD
Fosaprepitant—Feeling abnormal—Prednisone—Crohn's disease	0.0011	0.00188	CcSEcCtD
Fosaprepitant—Gastrointestinal pain—Prednisone—Crohn's disease	0.0011	0.00187	CcSEcCtD
Fosaprepitant—Urticaria—Prednisone—Crohn's disease	0.00106	0.00182	CcSEcCtD
Fosaprepitant—Body temperature increased—Prednisone—Crohn's disease	0.00106	0.00181	CcSEcCtD
Fosaprepitant—Abdominal pain—Prednisone—Crohn's disease	0.00106	0.00181	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—UBE2D1—Crohn's disease	0.001	0.00243	CbGpPWpGaD
Fosaprepitant—Hypersensitivity—Prednisone—Crohn's disease	0.000987	0.00168	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—RIPK2—Crohn's disease	0.000974	0.00235	CbGpPWpGaD
Fosaprepitant—Asthenia—Prednisone—Crohn's disease	0.000961	0.00164	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—IL3—Crohn's disease	0.00095	0.00229	CbGpPWpGaD
Fosaprepitant—Pruritus—Prednisone—Crohn's disease	0.000948	0.00162	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—RASGRP1—Crohn's disease	0.000919	0.00222	CbGpPWpGaD
Fosaprepitant—Diarrhoea—Prednisone—Crohn's disease	0.000917	0.00156	CcSEcCtD
Fosaprepitant—Dizziness—Prednisone—Crohn's disease	0.000886	0.00151	CcSEcCtD
Fosaprepitant—Vomiting—Prednisone—Crohn's disease	0.000852	0.00145	CcSEcCtD
Fosaprepitant—Rash—Prednisone—Crohn's disease	0.000845	0.00144	CcSEcCtD
Fosaprepitant—Dermatitis—Prednisone—Crohn's disease	0.000844	0.00144	CcSEcCtD
Fosaprepitant—Headache—Prednisone—Crohn's disease	0.000839	0.00143	CcSEcCtD
Fosaprepitant—TACR1—GPCR downstream signaling—JAK2—Crohn's disease	0.000834	0.00201	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—SOCS1—Crohn's disease	0.000833	0.00201	CbGpPWpGaD
Fosaprepitant—Nausea—Prednisone—Crohn's disease	0.000796	0.00136	CcSEcCtD
Fosaprepitant—TACR1—Signaling by GPCR—TYK2—Crohn's disease	0.000794	0.00192	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—CXCL8—Crohn's disease	0.000761	0.00184	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—JAK2—Crohn's disease	0.000757	0.00183	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—SMAD3—Crohn's disease	0.000719	0.00174	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—CXCL8—Crohn's disease	0.000691	0.00167	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—IL2RA—Crohn's disease	0.000666	0.00161	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—TYK2—Crohn's disease	0.000469	0.00113	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—JAK2—Crohn's disease	0.000447	0.00108	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—CXCL8—Crohn's disease	0.000408	0.000986	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—IL6—Crohn's disease	0.000388	0.000938	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—STAT3—Crohn's disease	0.000328	0.000793	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—IL6—Crohn's disease	0.000229	0.000554	CbGpPWpGaD
